Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Influenza

  Free Subscription


Articles published in Drugs

Retrieve available abstracts of 33 articles:
HTML format



Single Articles


    September 2023
  1. BLAIR HA
    Remdesivir: A Review in COVID-19.
    Drugs. 2023;83:1215-1237.
    PubMed     Abstract available


    June 2023
  2. POLAK TB, Cucchi DGJ, Schelhaas J, Ahmed SS, et al
    Results from Expanded Access Programs: A Review of Academic Literature.
    Drugs. 2023;83:795-805.
    PubMed     Abstract available


    May 2023
  3. CHEN TY, Wang SI, Hung YM, Hartman JJ, et al
    Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
    Drugs. 2023;83:621-632.
    PubMed     Abstract available


    February 2023
  4. KEAM SJ
    Nirsevimab: First Approval.
    Drugs. 2023;83:181-187.
    PubMed     Abstract available


  5. XIE J, Brash JT, Turkmen C, Driessen S, et al
    Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
    Drugs. 2023;83:249-263.
    PubMed     Abstract available


    January 2023
  6. PLOCQUE A, Mitri C, Lefevre C, Tabary O, et al
    Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
    Drugs. 2023;83:1-36.
    PubMed     Abstract available


    August 2022
  7. HOY SM
    Amubarvimab/Romlusevimab: First Approval.
    Drugs. 2022;82:1327-1331.
    PubMed     Abstract available


    July 2022
  8. DHILLON S
    Desidustat: First Approval.
    Drugs. 2022;82:1207-1212.
    PubMed     Abstract available


    June 2022
  9. KEAM SJ
    Tixagevimab + Cilgavimab: First Approval.
    Drugs. 2022;82:1001-1010.
    PubMed     Abstract available


  10. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    PubMed     Abstract available


    March 2022
  11. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    PubMed     Abstract available


  12. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    PubMed     Abstract available


  13. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    PubMed     Abstract available


    February 2022
  14. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.
    PubMed    


  15. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.
    PubMed    


    January 2022
  16. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    PubMed     Abstract available


    December 2021
  17. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    PubMed     Abstract available


  18. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    PubMed     Abstract available


    November 2021
  19. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    PubMed     Abstract available


    September 2021
  20. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.
    PubMed    


  21. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.
    PubMed    


    July 2021
  22. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.
    PubMed    


    June 2021
  23. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.
    PubMed    


    April 2021
  24. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    PubMed     Abstract available


  25. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    PubMed     Abstract available


  26. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    PubMed     Abstract available


    March 2021
  27. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    PubMed     Abstract available


    December 2020
  28. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    PubMed     Abstract available


    October 2020
  29. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    PubMed     Abstract available


  30. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    PubMed     Abstract available


    September 2020
  31. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.
    PubMed    


  32. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.
    PubMed    


  33. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.